JPMorgan Chase & Co. Buys 22,732 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

JPMorgan Chase & Co. increased its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 14.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 177,793 shares of the company's stock after acquiring an additional 22,732 shares during the period. JPMorgan Chase & Co. owned approximately 0.42% of SI-BONE worth $2,486,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. FMR LLC increased its stake in SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after acquiring an additional 1,198 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of SI-BONE in the second quarter valued at about $61,000. Walleye Capital LLC acquired a new stake in shares of SI-BONE in the third quarter valued at about $144,000. Deerfield Management Company L.P. Series C acquired a new stake in shares of SI-BONE in the second quarter valued at about $151,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of SI-BONE by 7.5% in the second quarter. The Manufacturers Life Insurance Company now owns 15,880 shares of the company's stock valued at $205,000 after buying an additional 1,105 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.

SI-BONE Stock Performance

SIBN stock traded up $0.38 during trading on Tuesday, reaching $17.07. 58,162 shares of the company's stock were exchanged, compared to its average volume of 328,232. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $21.64. The company's fifty day moving average price is $13.83 and its 200-day moving average price is $14.36. The firm has a market cap of $715.75 million, a PE ratio of -18.55 and a beta of 1.16.

Insider Transactions at SI-BONE

In other news, CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the transaction, the chief financial officer now owns 189,319 shares in the company, valued at approximately $2,633,427.29. The trade was a 2.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Laura Francis sold 10,048 shares of the business's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.58, for a total value of $126,403.84. Following the completion of the transaction, the chief executive officer now owns 482,875 shares in the company, valued at $6,074,567.50. This trade represents a 2.04 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,348 shares of company stock valued at $356,349. Corporate insiders own 3.90% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Truist Financial raised their price objective on SI-BONE from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Needham & Company LLC restated a "buy" rating and set a $19.00 price objective on shares of SI-BONE in a research note on Monday, January 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $23.00.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.